Trial Profile
Phase II trial of seasonal influenza virus vaccine (NasoVAX)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 10 May 2017
Price :
$35
*
At a glance
- Drugs ADhVN120304.H5 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Therapeutic Use
- 04 May 2017 According to an Altimmune media release, this study is expected to commence during 3Q of 2017 with initial data expected in 1Q of 2018.
- 19 Jan 2017 According to a PharmAthene media release, this study is expected to commence during mid-2017 with initial data expected in the fourth quarter of 2017.
- 24 Feb 2015 New trial record